Validate the Difficulty Scoring System and Develop a Novel Scoring System for Laparoscopic and Robotic Liver Resections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-16

Study Completion Date

2024-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To validate the Iwate difficulty scoring system and Institut Mutualiste Montsouris (IMM) scoring system (Appendix 2) in both laparoscopic and robotic liver resections

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Preoperative Score Predicting Outcome Following Liver Resection

NCT01003197

Serious Complications Following Liver Resection

COMPLETED

A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy

NCT04422249

Hepatocellular Carcinoma

RECRUITING NA

Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma

NCT02526043

Hepatocellular Carcinoma

UNKNOWN NA

Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy

NCT02533193

Liver Diseases

COMPLETED NA

A Novel MSE Score to Predict rHCC Patients

NCT05450874

HCC

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Minimally-invasive liver resections (MILR) are increasingly conducted world-wide today. Several international consensus meetings were convened to enable the safe dissemination of laparoscopic and robotic liver resections. The Iwate difficulty scoring system (Appendix 1) was formulated in Japan to grade the difficulty of liver resections. This was to allow beginners to adopt a stepwise approach to safely perform MILR according to their experience and competency level. Although this system has been recently validated in a recent Japanese multicenter study, it has not been externally validated in a large cohort of patients. Thus far, it has only been validated in several small single center studies. Furthermore, its utility for robotic liver resections has not been well-studied.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who underwent MILR from January 1, 2000 to December 31, 2020

Hospital of patients who underwent MILR from January 1, 2000 to December 31, 2020.

Minimally Invasive Liver Resection

Intervention Type PROCEDURE

laparoscopic and robotic liver resections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minimally Invasive Liver Resection

laparoscopic and robotic liver resections

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All consecutive patients operated at a single institution during a fixed period
* Most recent operation date allowed (up till December 31, 2020, to allow three months follow-up).
* All minimally invasive hepatectomy approaches can be included, including lap- assisted (hybrid), hand-assisted, robotic-assisted and pure laparoscopy.
* The data of all patients including those that had repeat liver resections, concomitant surgeries (e.g. colectomies, hilar lymph node dissection, enbloc resections) may be included
* Patients with no "liver tumors" such as recurrent pyogenic cholangitis/ gallbladder may be included
* The site of the "lesion/ pathology" will be considered as the tumor site, size will be considered less than 3 cm unless tumor invades the liver.